Do COVID-19 infection among patients increase the risk of Alzheimer’s disease?

Document Type : Letter to the Editor


1 Department of Science, School of Science and Technology, The Open University of Hong Kong, Ho Man Tin, Kowloon, Hong Kong

2 School of Graduate Studies, Lingnan University, Tuen Mun, Hong Kong

3 Key Laboratory of Molecular Target and Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China


The COVID-19 outbreak has occurred for more than ten months. Some COVID-19 complications are still unknown. Is there any long-term effect on the neurologic manifestations after COVID-19? Will the infected patient get a greater risk of Alzheimer’s disease? May the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have a long latency period in the Central Nervous System (CNS)? If this is possible, it has various non-specific inflammatory diseases that initiate and re-activate certain inflammatory or oxidative reactions in Alzheimer’s disease, but the neurological complications of COVID-19 are limited to individual cases or small case series according to several published papers.
Recently, Varatharaj et al. reported the neurological and neuropsychiatric complications of COVID-19 in 153 patients who were divided into two groups, cerebrovascular and neuropsychiatric. 96% of patients with cerebrovascular events are also altered with mental status in the age range from 71 to 80. The results showed 43% of patients with neuropsychiatric disorders would have a new-onset psychosis such as neurocognitive, dementia, and Alzheimer’s disease. (To be continued)...


Main Subjects